Headlines about Foundation Medicine (NASDAQ:FMI) have been trending somewhat positive this week, according to Alpha One Sentiment. The research firm, a unit of Accern, scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foundation Medicine earned a news sentiment score of 0.23 on Alpha One’s scale. Alpha One also gave media headlines about the company an impact score of 52 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have effected AlphaOne’s analysis:
- ETFs with exposure to Foundation Medicine, Inc. : June 16, 2017 (finance.yahoo.com)
- -$1.08 EPS Expected for Foundation Medicine, Inc. (FMI) This Quarter (americanbankingnews.com)
- Foundation Medicine : to Identify Patients Eligible for National Cancer Institute’s NCI-MATCH Molecular Analysis for Therapy Choice Study (4-traders.com)
- Foundation Medicine, Inc. :FMI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 (finance.yahoo.com)
- US genomic cancer profiling firm FMI heading for China, where access to new therapies lags (cnbc.com)
A number of research analysts have recently commented on FMI shares. Zacks Investment Research raised shares of Foundation Medicine from a “sell” rating to a “hold” rating in a research report on Thursday, March 9th. William Blair reissued a “buy” rating on shares of Foundation Medicine in a research report on Monday, April 3rd. Janney Montgomery Scott raised shares of Foundation Medicine from a “sell” rating to a “neutral” rating and set a $31.00 target price on the stock in a research report on Tuesday, March 7th. BTIG Research raised shares of Foundation Medicine from a “neutral” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Monday, May 15th. Finally, ValuEngine raised shares of Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Foundation Medicine currently has a consensus rating of “Hold” and a consensus target price of $30.25.
Shares of Foundation Medicine (FMI) traded down 3.57% during mid-day trading on Friday, hitting $37.80. 845,381 shares of the company’s stock were exchanged. The company’s market capitalization is $1.35 billion. The firm has a 50 day moving average price of $37.67 and a 200-day moving average price of $28.24. Foundation Medicine has a 52 week low of $16.95 and a 52 week high of $43.15.
Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.02) by $0.29. The company had revenue of $26.32 million for the quarter, compared to the consensus estimate of $29.07 million. Foundation Medicine had a negative net margin of 126.17% and a negative return on equity of 80.75%. The firm’s revenue was down 13.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.50) earnings per share. On average, equities analysts anticipate that Foundation Medicine will post ($4.36) EPS for the current year.
In other news, COO Steven J. Kafka sold 2,157 shares of the firm’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $31.96, for a total value of $68,937.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jason Ryan sold 5,573 shares of the firm’s stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $40.00, for a total value of $222,920.00. Following the completion of the sale, the chief financial officer now owns 78,405 shares of the company’s stock, valued at $3,136,200. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,196 shares of company stock valued at $642,582. Company insiders own 2.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Foundation Medicine (FMI) Earning Somewhat Positive News Coverage, Study Shows” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/06/16/somewhat-positive-media-coverage-somewhat-likely-to-impact-foundation-medicine-fmi-stock-price-updated.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.